ALPS Medical Breakthroughs ETFSBIO
SBIO
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
371% more call options, than puts
Call options by funds: $33K | Put options by funds: $7K
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
4.98% less ownership
Funds ownership: 52.44% [Q3] → 47.46% (-4.98%) [Q4]
5% less funds holding
Funds holding: 37 [Q3] → 35 (-2) [Q4]
7% less capital invested
Capital invested by funds: $53M [Q3] → $49.1M (-$3.85M) [Q4]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Research analyst outlook
We haven’t received any recent analyst ratings for SBIO.
Financial journalist opinion
Neutral
ETF Trends
1 month ago
This Tech Sector ETF Could Zig Where Others Zag
With tech earnings arriving, many investors are still likely fearing a downturn for key information technology stocks. The so-called Magnificent Seven stocks delivered significant performance for investors last year.
Neutral
Seeking Alpha
1 month ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
ETF Trends
2 months ago
Healthcare Stocks Could Merit Prescriptions in 2025
It's been a long road of disappointment for healthcare stocks. And biotechnology names have been among the worst offenders.
Negative
Seeking Alpha
4 months ago
SBIO ETF: Betting On Medical Breakthroughs
ALPS Medical Breakthroughs ETF is rated Hold due to high fees, low yield, and mixed performance compared to other healthcare ETFs. The SBIO ETF focuses on small and mid-cap biotech companies with drugs in Phase II or III FDA trials, offering targeted exposure to medical breakthroughs. Despite an aging population driving healthcare demand, sector headwinds and government budget pressures make healthcare stocks less attractive for generating Alpha.
Positive
ETF Trends
4 months ago
Biotech Looms as a Way to Beat the Market
Could now be the time to diversify into important tech subsectors? Rate cuts may already be benefiting tech sectors by easing borrowing costs, with more cuts potentially in the offing.
Positive
ETF Trends
4 months ago
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Positive
ETF Trends
5 months ago
Steady Rate Cuts Feed Surging Biotech ETF SBIO
Yet another rate cut has come and gone, and even with somewhat steady inflation reads, further cuts may be in the pipeline. Debt-heavy areas like tech stand to benefit, but for those already heavily exposed to big tech names, looking elsewhere may appeal.
Positive
ETF Trends
5 months ago
How Election Results Could Impact Biotech ETFs
Biotech stocks and ETFs are among the assets that responded positively to last week's presidential election results. As just one example, the ALPS Medical Breakthroughs ETF (SBIO) is up 10% for the week ending November 11.
Positive
ETF Trends
5 months ago
Biotech ETF SBIO Laps Tech Rivals Over 1 Year
If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.
Neutral
Business Wire
6 months ago
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symbol: SBIO), with offices in Dubai and provider of AI models for data generated in the new space industry economy, have signed a Letter of Intent (LOI) to partner on joint satellite payload design and development of CubeSats along with measuring radiation and launching payloads for biotechnology, pharmaceutical compani.
Charts implemented using Lightweight Charts™